Login
Subscribe
Take a FREE Trial
About Us
Contact us
RSS
22 May 2013
Search
The Pharma Letter
Home
7 Day Premium Trial
Pharmaceuticals
Biotechnology
Generics
Events
Companies
Drugs
Subscribe
Companies
Top Ten Companies //
Browse A - Z of companies
Merck KGaA
(Merck)
Merck
(Merck KGaA)
Pfizer
Roche
Novartis
GlaxoSmithKline
(GSK)
GSK
(GlaxoSmithKline)
Bristol-Myers Squibb
Lilly
Bayer
Browse the A - Z of Companies
#
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
I
I'rom Pharmaceutical
IBA Molecular
iBIO
IBSA
Icagen
IDC-GP Pharm
Idenix Pharmaceuticals
Idera Pharmaceuticals
Idun Pharmaceuticals
IGDRASOL
Ignyta
Ikaria
Ildong Pharma
Illumina
Ilsanta
ImaginAb
Imaxio
IMCD Group
ImClone Systems
Immdal
Immune Design Corp
Immune Pharmaceuticals
ImmuNext
ImmunoGen
Immunomedics
Immunovaccine
ImmuPharma
Immuron
Immutep
Impax Laboratories
Inbiopro Solutions
Incepta Pharmaceuticals
Incline Therapeutics
InCube Labs
Incyte
Indar
IndChem
Indchemie Health Specialties
Index Ventures
Indicia Production
Industrifonden
Infinity Pharmaceuticals
InGen BioSciences
Inhibitex
Innate Pharma
InnoKeys PTE
InnoPharma
Innovent Biologics
iNova
Inovio Pharma
Inserm
Insight Bioventures
Insmed
Inspiration Biopharmaceuticals
Inspire Pharmaceuticals
Institut Pasteur
Insys Therapeutics
Intarcia Therapeutics
Intas Pharmaceuticals
Intellect Neuroscience
Intellikine
Intellipharmaceutics
Intercell
Intercept Pharmaceuticals
InterMune
International Specialty Products
International Stem Cell
InterPharma
Intra-Cellular Therapies
Intrexon
Invida
Invidia Group
Inviragen
Ion Torrent
Ipca Laboratories
iPS Academia Japan
Ipsen
Ipsogen
Ironwood Pharmaceuticals
IS Pharma
IS Pharma
Isis Pharmaceuticals
Islet Sciences
Isotechnika
ISTA Pharmaceutical
Itero Biopharmaceuticals
IVAL Pharma
Ivax
Ivax Pharmaceuticals
Izvarino Pharma
Hot Topics
Most Read
Is failure to adopt business process management putting the pharma industry at risk?
Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
New Zealand declines Alexion's funding application for Solaris
AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
Is failure to adopt business process management putting the pharma industry at risk?
Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
New Zealand declines Alexion's funding application for Solaris
AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations